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Abstract: 
Recently, we developed a risk score for antiphospholipid syndrome (APS) (Global APS Score or GAPSS). This 
score derived from the combination of independent risk factors for thrombosis and pregnancy loss, taking 
into account the antiphospholipid antibodies (aPL) profile (criteria and non-criteria aPL), the conventional 
cardiovascular risk factors, and the autoimmune antibodies profile. We demonstrate that risk profile in APS 
can be successfully assessed, suggesting that GAPSS can be a potential quantitative marker of APS-related 
clinical manifestations. Lupus (2014) 23, 1286–1287.  
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Introduction  
One of the cornerstones of health and clinical research is to identify individuals who have a high risk of 
developing an adverse outcome over a specific time period, so that they can be targeted for early 
preventative strategies and possibly treatment. Many prediction models have been developed for 
cardiovascular disease,1,2 mainly focusing on stroke or ischaemic heart events. More recently, three score 
systems have been formulated to quantify the risk of thrombosis/ obstetric events in antiphospholipid 
syndrome (APS), aiming to help physicians to stratify patients according to risk.3–5 The first two scores3,4 
focused on the antiphospholipid antibodies (aPL) profile, while the most recent one, The Global APS Score 
or GAPSS,5 also included the cardiovascular risk factors and autoimmune profile when the risk was 
computed. 
The Global APS Score (GAPSS)  
The Global APS Score (GAPSS) was designed and developed in a large cohort of patients with systemic lupus 
erythematosus (SLE).5 It is derived from the combination of independent risk factors for thrombosis and 
pregnancy loss. GAPSS takes into account the aPL profile, including criteria6 and non-criteria aPL7 as well as 
conventional cardiovascular risk factors such as arterial hypertension, smoking, hyperlipidaemia and 
diabetes and the autoimmune antibodies profile (ANA, ENA and anti-dsDNA) into the equation. The GAPSS 
was developed and validated in a large cohort of consecutive SLE patients who were randomly divided into 
two sets by a computer-generated randomized list. The GAPSS was developed in the first set of 106 SLE 
patients, assigning weighted points proportional to the b-regression-coefficient values to each of the risk 
factors identified by multivariate analysis (Table 1). In this cohort, higher values of GAPSS were seen in 
patients who experienced thrombosis and/or pregnancy loss compared with those without clinical events 
(GAPSS 9.3 4.8 [range 1–19] and 5.3 4 [range 0–16], p < 0.001). The GAPSS was then computed and 
validated in the second set of 105 patients with SLE. In this validation cohort the results were similar, with 
statistically higher GAPSS values in patients with a clinical history of thrombosis and/or pregnancy loss 
compared with those without events (GAPSS 9.5 5.6 [range 0–20] and 3.9 4.1 [range 0–17], p < 0.001). The 
GAPSS score was also evaluated in a cohort of 51 SLE patients prospectively followed-up.8 In this study, we 
showed that an increase in the GAPSS during the follow-up (mean 32.94 12.06 months) was seen in those 
SLE patients who experienced vascular events when compared with those who did not experience such an 
event with a RR 12.30 (95%CI 1.43–106.13, p ¼ 0.004). Specifically, an increase of more than 3 GAPSS 
points had the best risk accuracy for vascular events (HR 48 [95%CI 6.90–333.85, p ¼ 0.0001]) in this 
cohort.8 In order to evaluate the clinical relevance of the GAPSS in patients without an underlying 
connective tissue disease, we recently performed a study including 62 consecutive patients with primary 
APS (PAPS).9 In this study, we showed that higher values of GAPSS were seen in patients with PAPS who 
experienced thrombosis when compared with those with pregnancy loss alone. In addition, we reported 
that PAPS patients who experienced recurrent thrombotic events showed higher GAPSS when compared 
with those without recurrences. Interestingly, GAPSS values higher or equal to 11 were strongly associated 
with a higher risk of recurrences (OR 18.27, 95%CI 3.74–114.5) and seemed to have the best risk accuracy, 
in terms of sensitivity and specificity. In summary, GAPSS is a score model based on six clinical factors (four 
aPL specificities, arterial hypertension and hyperlipidaemia) that has been proven to represent the 
‘probability’ or likelihood of having thrombosis or pregnancy loss in SLE. More recently, the clinical 
relevance of the GGAPSS in patients without an underlying connective tissue disease has also been proven. 
The strength of GAPSS, when compared with the previous proposed scores, lies in the inclusion of 
conventional cardiovascular risk factors into the computation. GAPSS may represent a useful tool to assess 
the thrombosis or pregnancy loss risk for each aPLpositive patient, switching from the concept of aPL as 
diagnostic antibodies to aPL as risk factors for clinical events. Needless to say, although promising, its use 
should be independently validated in prospective cohorts. 
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